<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636243</url>
  </required_header>
  <id_info>
    <org_study_id>NIMAO/2017-02/APM-01</org_study_id>
    <nct_id>NCT03636243</nct_id>
  </id_info>
  <brief_title>Comparative Evaluation of the Evolution of Arterial and Microcirculatory Endothelial Function in Obese Patients With Type-2 Diabetes Versus Non-diabetic Obese Patients After a First Bariatric Surgery</brief_title>
  <acronym>BariVaDia</acronym>
  <official_title>Comparative Evaluation of the Evolution of Arterial and Microcirculatory Endothelial Function in Obese Patients With Type-2 Diabetes Versus Non-diabetic Obese Patients After a First Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The weight reduction obtained after a first bariatric surgery would improve the vascular
      (correction of endothelial dysfunction, improvement of arterial wall compliance and evolution
      of the atherothrombotic process) and microcirculatory function in obese patients with type-2
      diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>day -15</time_frame>
    <description>Measured to the finger by tonometry using the &quot;Endo-Pat 2000 device&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>Month 3</time_frame>
    <description>Measured to the finger by tonometry using the &quot;Endo-Pat 2000 device&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>day -15, Month 12</time_frame>
    <description>reactive hyperemia index (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the vascular endothelial growth factor marker of endothelial function in both groups and between groups</measure>
    <time_frame>day -15</time_frame>
    <description>pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the vascular endothelial growth factor marker of endothelial function in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the vascular endothelial growth factor marker of endothelial function in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the soluble fms-like tyrosine kinase-1 markers of endothelial function in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the soluble fms-like tyrosine kinase-1 markers of endothelial function in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the soluble fms-like tyrosine kinase-1 markers of endothelial function in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>pg/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the fibrinogen marker of endothelial function in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the fibrinogen marker of endothelial function in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the fibrinogen marker of endothelial function in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>g/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the D-dimer marker of endothelial function in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the D-dimer marker of endothelial function in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the concentration of the D-dimer marker of endothelial function in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the physical activity</measure>
    <time_frame>Day -15</time_frame>
    <description>number of steps in previous 4 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the physical activity</measure>
    <time_frame>Month 3</time_frame>
    <description>number of steps in previous 4 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the physical activity</measure>
    <time_frame>Month 12</time_frame>
    <description>number of steps in previous 4 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creation of a biobank</measure>
    <time_frame>Day -15</time_frame>
    <description>storage of blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creation of a biobank</measure>
    <time_frame>Month 3</time_frame>
    <description>storage of blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creation of a biobank</measure>
    <time_frame>Month 12</time_frame>
    <description>storage of blood sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare toe pressure using the SysToe device in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare toe pressure using the SysToe device in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare toe pressure using the SysToe device in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the sweat function using the&quot; Sudoscan&quot; device in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>µV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the sweat function using the &quot;Sudoscan&quot; device in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>µV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the sweat function using the &quot;Sudoscan&quot; device in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>µV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the vibratory sensitivity using a neurothesiometer in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>Hz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the vibratory sensitivity using a neurothesiometer in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Hz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the vibratory sensitivity using a neurothesiometer in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>Hz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the sensitive conduction velocity in both groups and between groups</measure>
    <time_frame>Day -15</time_frame>
    <description>m/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the sensitive conduction velocity in both groups and between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>m/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the sensitive conduction velocity in both groups and between groups</measure>
    <time_frame>Month 12</time_frame>
    <description>m/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the presence of neuropathic pain using the questionnaire &quot;Neuropathic Pain in 4 Questions&quot;</measure>
    <time_frame>Day -15</time_frame>
    <description>If the score is greater than or equal to 4, the test is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the presence of neuropathic pain using the questionnaire &quot;Neuropathic Pain in 4 Questions&quot;</measure>
    <time_frame>Month 3</time_frame>
    <description>If the score is greater than or equal to 4, the test is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the presence of neuropathic pain using the questionnaire &quot;Neuropathic Pain in 4 Questions&quot;</measure>
    <time_frame>Month 12</time_frame>
    <description>If the score is greater than or equal to 4, the test is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life using the &quot;Quality Of Life, Obesity and Dietetics&quot; questionnaire</measure>
    <time_frame>Day -15</time_frame>
    <description>It has 36 items, rated from 1 (always / enormously) to 5 (never / not at all). It explores five dimensions (physical impact - Q1-Q11, psychosocial impact - Q12-Q22, impact on sex life - Q23-Q26, nutritional well-being - Q27-Q31 and diet experience - Q32-Q36). The rating of each dimension is reported at 100. The higher the score is close to 100, the better the quality of life related to this dimension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life using the &quot;Quality Of Life, Obesity and Dietetics&quot; questionnaire</measure>
    <time_frame>Month 3</time_frame>
    <description>It has 36 items, rated from 1 (always / enormously) to 5 (never / not at all). It explores five dimensions (physical impact - Q1-Q11, psychosocial impact - Q12-Q22, impact on sex life - Q23-Q26, nutritional well-being - Q27-Q31 and diet experience - Q32-Q36). The rating of each dimension is reported at 100. The higher the score is close to 100, the better the quality of life related to this dimension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life using the &quot;Quality Of Life, Obesity and Dietetics&quot; questionnaire</measure>
    <time_frame>Month 12</time_frame>
    <description>It has 36 items, rated from 1 (always / enormously) to 5 (never / not at all). It explores five dimensions (physical impact - Q1-Q11, psychosocial impact - Q12-Q22, impact on sex life - Q23-Q26, nutritional well-being - Q27-Q31 and diet experience - Q32-Q36). The rating of each dimension is reported at 100. The higher the score is close to 100, the better the quality of life related to this dimension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of post-ischemic hyperemia using the laser doppler Perimed.</measure>
    <time_frame>Day -15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of post-ischemic hyperemia using the laser doppler Perimed.</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of post-ischemic hyperemia using the laser doppler Perimed.</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of cutaneous vasomotion using the laser doppler Perimed.</measure>
    <time_frame>Day -15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of cutaneous vasomotion using the laser doppler Perimed.</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of cutaneous vasomotion using the laser doppler Perimed.</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bariatric Surgery</condition>
  <condition>Obese</condition>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vascularly biological assessment</intervention_name>
    <description>22.5 ml of blood will be collected at day -15, month 3 and month 12.</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Analysis of vasomotor endothelial function</intervention_name>
    <description>Evaluation of the peripheral endothelial function by digital tonometry using the 'EndoPATTM2000' system [Itamar Medical Ltd., Caeserea, Israel] before and after induction of post occlusive reactive hyperemia at day -15, month 3 and month 12.</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Analysis of arterial compliance</intervention_name>
    <description>Evaluation of the aortic pulse wave velocity in the aortofemoral segment or in the periphery (on the arm-ankle segment) by calculation of central aortic pressure (CAP) using the tonometric system 'Complior ™' [Alam Medical, France] at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Exploration of microcirculation</intervention_name>
    <description>The microcirculation exploration via analysis of the curves recorded by Laser Doppler at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Venous Doppler Ultrasound</intervention_name>
    <description>aneurysm screening at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Arterial pressure measurement</intervention_name>
    <description>measurement of the systolic pressure at the toe using the SysToe™ device, and measurement of systolic and diastolic blood pressure using the Dinamap™ device at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intima-Media Thickness measurement</intervention_name>
    <description>Intima-Media Thickness measurement using an ultrasound machine at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Exploration of neuropathy</intervention_name>
    <description>non-invasive measurement of sudomotor function by SUDOSCAN at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>level of physical activity</intervention_name>
    <description>pedometer collecting the number of steps during the four days before visits at day -15, month 3 and month 12</description>
    <arm_group_label>Group of non-diabetic obese patients</arm_group_label>
    <arm_group_label>Group of obese patients with type-2 diabetes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is at least 18 years old and under 70 years old

          -  The patient is available for a follow-up of 12 months

          -  The patient signed the consent form

          -  The patient must be affiliated or beneficiary to an health care plan

          -  The patient is followed in hospital day care in the endocrine and metabolic disorders
             department at Nimes University Hospital for a first bariatric surgery

        Exclusion Criteria:

          -  The subject participates in another interventional study.

          -  The subject is in an exclusion period determined by a previous study.

          -  The subject is under the protection of justice, guardianship or curatorship.

          -  The subject refuses to sign the consent.

          -  It is not possible to give the subject informed information.

          -  The patient is pregnant or breastfeeding.

          -  Subject with known advanced atherothrombotic disease (arterial disease of the lower
             limbs, significant carotid plaque (generating stenosis&gt; 50%), history of myocardial
             infarction, stroke)

          -  The subject is type 1 diabetic.

          -  The subject has already had a bariatric surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonia PEREZ-MARTIN, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nîmes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonia PEREZ-MARTIN, Pr</last_name>
    <phone>+33(0)4.66.68.33.13</phone>
    <email>antonia.perez.martin@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.30.52</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Marie Guedj, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique TAILLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Christophe GRIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvie BOUVIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ion DONICI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel PRUDHOMME, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle AICHOUN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sarah COUDRAY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérémy LAURENT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>November 5, 2019</last_update_submitted>
  <last_update_submitted_qc>November 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

